Reading RYTM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RYTM free→Reading RYTM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RYTM free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is steady. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 202% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $89.70. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $90, RYTM's earnings are too small for P/E to mean much; on sales it trades at 32× p/s (3.4× the 9× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $31 fair value covers only the as-is business, low confidence. Analysts: $125–$155. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 186% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 18.85x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.82 → $-0.84 (-3.2% / 30d). 4 raised, 6 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d. 94% of analysts rate Buy.
2 PT revisions / 30d. Avg target 57.9% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$210.
How much price usually moves either way.
On a bad day, this stock has moved -$431.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,554.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show if Rhythm can improve its financial situation. Investors will look for signs of recovery.
Confirms one read:The earnings report shows revenue growth. It also shows smaller losses than before.
Confirms the other:The earnings report shows ongoing losses. It also shows a drop in revenue.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RYTM yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 13, 2026, Rhythm announced interim six-month data from its exploratory Phase 2 trial of setmelanotide in patients with PWS, which are summarized below. Rhythm enrolled 18 patients with PWS aged 6-23 years old with a BMI ≥30 kg/m 2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients younger than 18 in this Phase 2 trial. The 52-week trial remains ongoing, and 17 patients remain on active therapy as of June 12, 2026. Results from the six-mont…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$125.00 – $155.00 (median $143.00) · 8 analysts · as of 2026-06-15
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RYTM Rhythm Pharmaceuticals, Inc. | Typical Show detailsSector percentile: 54 of 100 | expensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Expand the market authorization for IMCIVREE to include treatment of acquired hypothalamic obesity.
Newly stated in 2026-Q1. The European Medicines Agency's positive opinion to expand IMCIVREE's market authorization for acquired hypothalamic obesity was announced. This expansion is a strategic growth initiative, but financial impact is not yet reflected in the revenue figures.
“EMA's positive opinion recommending to expand the current marketing authorization for IMCIVREE.”
Maintain non-GAAP operating expenses between $385 million and $415 million for the fiscal year 2026.
Stated in 2 of last 2 quarters. Rhythm has maintained its guidance for non-GAAP operating expenses between $385 million and $415 million for 2026. However, the financials show a net income loss of $55.6 million in 2026-Q1, indicating limited progress in cost management so far.
“Rhythm anticipates approximately $385 million to $415 million in Non-GAAP Operating Expenses.”
Focus on increasing revenue from global sales of IMCIVREE, targeting significant growth year over year.
Newly stated in 2025-Q4. Revenue from IMCIVREE grew from $130 million in 2024 to $194 million in 2025, a 50% increase. This growth aligns with management's focus on expanding IMCIVREE sales, indicating positive trajectory in revenue generation.
Why it matters: If healthcare sector revenue growth speeds up, it could help Rhythm's performance. This signals a better market environment.
Confirms:Healthcare sector revenue growth rises back toward 10% or higher.
Disproves:Healthcare sector revenue growth remains below 10% or continues to slow.
and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press release dated May 5, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: May 5, 2026 By: /s/ Hunter C. Smith Hunter C. Smith Chief Fina…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On April 1, 2026, the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) elected Kimberly J. Popovits as a non-employee director of the Company, effective on the same date. Ms. Popovits will serve as a Class II director to hold office until the Company’s 2028 annual meeting of stockholders and until her successor is…
Other Events. On March 26, 2026, Rhythm announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE ® (setmelanotide) to include the treatment of obesity and the control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The CHMP opinion will now be reviewed…
Regulation FD Disclosure. On March 26, 2026, Rhythm Pharmaceuticals, Inc. (“Rhythm”) issued a press release announcing that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE ® (setmelanotide) to include the treatment of obesity and the control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hyp…
“Rhythm anticipates approximately $385 million to $415 million in Non-GAAP Operating Expenses.”
“Net product revenues for the full year of 2025 are expected to be approximately $194 million, compared to $130 million for 2024.”